oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 14 )

2018 ( 22 )

2017 ( 22 )

2016 ( 27 )

Custom range...

Search Results: 1 - 10 of 17354 matches for " Federico; Castro-Laria "
All listed articles are free for downloading (OA Articles)
Page 1 /17354
Display every page Item
Perineal pyoderma gangrenosum in a girl treated with adalimumab after infliximab failure Pioderma gangrenoso perineal en una ni a tratado con adalimumab tras fallo a infliximab
Luisa Castro-Laria,Federico Argüelles-Arias,Manuel García-Martín,Susana Jiménez-Contreras
Revista Espa?ola de Enfermedades Digestivas , 2011,
Abstract:
Is safety infliximab during pregnancy in patients with inflammatory bowel disease? El tratamiento con infliximab es seguro durante el embarazo en pacientes con enfermedad inflamatoria intestinal?
Federico Argüelles-Arias,Luisa Castro-Laria,Manuel Barreiro-de-Acosta,Ma Valle García-Sánchez
Revista Espa?ola de Enfermedades Digestivas , 2012,
Abstract: Background: in most cases, inflammatory bowel disease (IBD) debuts at reproductive age. The data available in the literature show infliximab (IFX) to be a safe drug during pregnancy but there is very little evidence about the activity of the disease following drug withdrawal during pregnancy. Aims: determine the drug′s safety in pregnant women in our setting and assess its effect on the foetus, drawing on the experience of several hospitals. Secondly, observe the effect of treatment withdrawal on disease activity during pregnancy. Material and methods: a retrospective study was conducted of women with IBD who had received IFX treatment during pregnancy in five hospitals in Spain. Disease activity was assessed using Crohn′s Disease Activity Index, while UC was assessed using the Truelove-Witts Index in each trimester of pregnancy. Gestational age, weight and diseases in the foetus were determined at birth. Results: the study included 12 women with a mean age of 29 years; 4 had ulcerative colitis and 8 Crohn′s disease, with mean disease duration of 7 years. All but one, who was diagnosed during pregnancy, was receiving IFX treatment at conception. Six patients received uninterrupted treatment throughout the pregnancy, 2 requested voluntary interruption and in 3 cases treatment was interrupted in the third trimester as a precaution. They received a mean IFX dose of 400 mg every 8 weeks. Of the 6 patients who received continuous treatment, in 50% disease was held in remission. The 6 remaining patients suspended treatment for different reasons, presenting disease recurrence in all but one case (83.3%). Eight deliveries were vaginal and 4 by caesarean section. Newborns presented no congenital anomalies, intrauterine growth retardation or low birth weight and there was only one premature delivery. Conclusions: although cases included in the stduy are not significant, in our experience, IFX during pregnancy is a safe treatment for the mother and the foetus. In fact, in our study and in some cases, its withdrawal may lead to a worsening of the disease. However, further control studies are required with larger samples to obtain more representative findings. Introducción: la enfermedad inflamatoria intestinal (EII) es un trastorno crónico que debuta en la mayoría de los casos durante la edad reproductiva. Existen pocos datos sobre la seguridad durante el embarazo de los tratamientos disponibles, entre ellos los denominados biológicos, y estos están basados en resultados de casos esporádicos. Objetivos: determinar la seguridad del tratamiento con infliximab (IFX) du
Is safety infliximab during pregnancy in patients with inflammatory bowel disease?
Argüelles-Arias,Federico; Castro-Laria,Luisa; Barreiro-de-Acosta,Manuel; García-Sánchez,Ma Valle; Guerrero-Jiménez,Pedro; Gómez-García,Ma Rosa; Cordero-Ruiz,Patricia; Iglesias-Flores,Eva; Gómez-Camacho,Federico; Domínguez-Mu?oz,Enrique J.; Herrerías-Gutiérrez,Juan Manuel;
Revista Espa?ola de Enfermedades Digestivas , 2012, DOI: 10.4321/S1130-01082012000200003
Abstract: background: in most cases, inflammatory bowel disease (ibd) debuts at reproductive age. the data available in the literature show infliximab (ifx) to be a safe drug during pregnancy but there is very little evidence about the activity of the disease following drug withdrawal during pregnancy. aims: determine the drug′s safety in pregnant women in our setting and assess its effect on the foetus, drawing on the experience of several hospitals. secondly, observe the effect of treatment withdrawal on disease activity during pregnancy. material and methods: a retrospective study was conducted of women with ibd who had received ifx treatment during pregnancy in five hospitals in spain. disease activity was assessed using crohn′s disease activity index, while uc was assessed using the truelove-witts index in each trimester of pregnancy. gestational age, weight and diseases in the foetus were determined at birth. results: the study included 12 women with a mean age of 29 years; 4 had ulcerative colitis and 8 crohn′s disease, with mean disease duration of 7 years. all but one, who was diagnosed during pregnancy, was receiving ifx treatment at conception. six patients received uninterrupted treatment throughout the pregnancy, 2 requested voluntary interruption and in 3 cases treatment was interrupted in the third trimester as a precaution. they received a mean ifx dose of 400 mg every 8 weeks. of the 6 patients who received continuous treatment, in 50% disease was held in remission. the 6 remaining patients suspended treatment for different reasons, presenting disease recurrence in all but one case (83.3%). eight deliveries were vaginal and 4 by caesarean section. newborns presented no congenital anomalies, intrauterine growth retardation or low birth weight and there was only one premature delivery. conclusions: although cases included in the stduy are not significant, in our experience, ifx during pregnancy is a safe treatment for the mother and the foetus. in fact, in our
Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
Patricia Cordero-Ruiz,C. Castro-Márquez,V. Méndez-Rufián,L. Castro-Laria
Revista Espa?ola de Enfermedades Digestivas , 2011,
Abstract: Background: adalimumab, a human anti-TNF, is an effective induction and maintenance therapy for patients with moderate to severe Crohn's disease. It seems to be effective in patients with resistance to infliximab, too, though the experience is more limited. Aim: to evaluate the efficacy of adalimumab, in patients with Crohn's disease (CD) and failure to previous treatment with infliximab. B twenty-five patients with CD and failure to previous treatment with infliximab were enrolled; they were treated with 160/80 (24 patients) and 80/40 (1 patient) induction doses. We analyze clinical response to treatment with adalimumab by the Crohn's disease Activity Index (CDAI) and plasma concentration of C-reactive protein (CRP), steroid sparing and complete fistula closure at week 48. Results: eighteen out of twenty-five patients (72%) achieved clinical remission (CDAI score < 150) at week 24 and 15/25 (60%) patients at week 48. There was a statistically significant difference (p < 0.01) in CRP serum levels from 21 to 8 mg/dl at week 48. Nine out of fifteen patients (60%) treated with corticosteroids were able to discontinue steroids. Three out of eleven patients (27%) with fistulizing Crohn's disease had complete fistula closure after the treatment. Seventy two percent of the patients (18/25) needed to increase adalimumab to weekly dose, in order to maintain clinical response. Five out of twenty-five patients (20%) had adverse events; two of them (8%) with serious adverse events (tuberculous meningitis and abdominal abscess) that forced the withdrawal of treatment. Conclusions: according to these data, adalimumab provides a clinical and analytical improvement in patients with CD and failure to previous therapy with infliximab. Introducción: adalimumab, un anti-TNF humano, ha demostrado ser efectivo en la inducción y tratamiento de mantenimiento de la enfermedad de Crohn moderada-grave. Existe menos experiencia, pero este fármaco parece también eficaz en los pacientes con pérdida de respuesta o intolerancia al infliximab. Objetivo: evaluar la eficacia de adalimumab durante un a o, en nuestra serie de pacientes con enfermedad de Crohn (EC) y fracaso en el tratamiento previo con infliximab. Métodos: se incluyen 25 pacientes con enfermedad de Crohn y fracaso previo a la terapia con infliximab, que son tratados con adalimumab. Se utilizaron dosis de inducción de 160/80 mg en 24 pacientes y dosis de 80/40 en un paciente. Analizamos la respuesta clínica al tratamiento con adalimumab mediante el índice de actividad de la enfermedad de Crohn (CDAI) y las concentraciones pl
Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series
Cordero-Ruiz,Patricia; Castro-Márquez,C.; Méndez-Rufián,V.; Castro-Laria,L.; Caunedo-álvarez,A.; Romero-Vázquez,J.; Herrerías-Gutiérrez,J. M.;
Revista Espa?ola de Enfermedades Digestivas , 2011, DOI: 10.4321/S1130-01082011000600003
Abstract: background: adalimumab, a human anti-tnf, is an effective induction and maintenance therapy for patients with moderate to severe crohn's disease. it seems to be effective in patients with resistance to infliximab, too, though the experience is more limited. aim: to evaluate the efficacy of adalimumab, in patients with crohn's disease (cd) and failure to previous treatment with infliximab. b twenty-five patients with cd and failure to previous treatment with infliximab were enrolled; they were treated with 160/80 (24 patients) and 80/40 (1 patient) induction doses. we analyze clinical response to treatment with adalimumab by the crohn's disease activity index (cdai) and plasma concentration of c-reactive protein (crp), steroid sparing and complete fistula closure at week 48. results: eighteen out of twenty-five patients (72%) achieved clinical remission (cdai score < 150) at week 24 and 15/25 (60%) patients at week 48. there was a statistically significant difference (p < 0.01) in crp serum levels from 21 to 8 mg/dl at week 48. nine out of fifteen patients (60%) treated with corticosteroids were able to discontinue steroids. three out of eleven patients (27%) with fistulizing crohn's disease had complete fistula closure after the treatment. seventy two percent of the patients (18/25) needed to increase adalimumab to weekly dose, in order to maintain clinical response. five out of twenty-five patients (20%) had adverse events; two of them (8%) with serious adverse events (tuberculous meningitis and abdominal abscess) that forced the withdrawal of treatment. conclusions: according to these data, adalimumab provides a clinical and analytical improvement in patients with cd and failure to previous therapy with infliximab.
Enfermedad inflamatoria intestinal y embarazo Intestinal bowel disease and pregnancy
L. Castro Laria,F. Candil del Olmo
Revista Espa?ola de Enfermedades Digestivas , 2007,
Abstract:
Cambio climático y protocolo de Kioto. Ciencia y estrategias: Compromisos para Espa?a
Velázquez de Castro González,Federico;
Revista Espa?ola de Salud Pública , 2005, DOI: 10.1590/S1135-57272005000200007
Abstract: this article presents climate change as the major environmental problem of our time. a result of the so-called "greenhouse effect", climate change is caused by certain gases, the concentrations in the atmosphere of which are growing exponentially. the consequences of these gases are going to be felt throughout the entire biosphere, from weather phenomenon to humans, creating a uncertain panorama which is going to be requiring some fast-paced adaptation on the part of all species. this is not, however, an irreversible process, taking action thus being possible and necessary, by combining education and lawmaking measures brought into being within the timeframes and to the extents set forth under the 1997 kyoto protocol. spain will be one of the most highly-affected countries, and its strategy may therefore mean a highly-valuable tool for correcting the deviations caused and contributing to the urgent control of global emissions.
Innovation in Retail Process: From Consumers’ Experience to Immersive Store Design
Pantano,Eleonora; Laria,Giuseppe;
Journal of technology management & innovation , 2012, DOI: 10.4067/S0718-27242012000300016
Abstract: due to the current advances in information and communication technologies and consumers’ increasing interest in entertaining and interactive retail environments, the sector of retailing is forced to pursuit innovation to maintain existing consumers and attract new ones. especially the use of virtual reality techniques offers tools for supporting the design of innovative systems capable of enhancing this process. the aim of this paper is to integrate the consumers’ experience in the development of innovation process for retailing. in particular, our findings highlight how the immersive technologies can be an efficient tool for pushing innovation in retailing. therefore, the paper provides important issues for scholars and practitioners.
Las tecnologías apropiadas de la salud: una aproximación del enfoque Ciencia- Tecnología- Sociedad al tema
Menéndez Laria,Aimeé;
Humanidades M??dicas , 2006,
Abstract: health situation in contemporary world demands to society to place in a firth level of analysis questions like justness, promotion and prevention of health, quality of the attention, the ethical dilemmas, the recognition of the technological necessities of health in the national policy as an important factor for its development, and the use of proper technologies. for this reason of the most up-to-date literature in the last aspect, is made, with the purpose of contributing to the knowledge and broadcasting of a controversial but effective topic
Las tecnologías apropiadas de la salud bucal: un enfoque diferente
Menéndez Laria,Aimeé;
Revista Cubana de Estomatolog?-a , 2006,
Abstract: the health situation of the contemporary world demands from society to analyze in the first place questions such as equity, health promotion and prevention, the quality of attention, the ethical dilemmas, the recognition of the technological health needs in the national policy as a key factor for its development, and the use of appropriate technologies. to this end, a review of the most updated literature on this topic was made to contribute to the knowledge and dissemination of a discussed, but present topic.
Page 1 /17354
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.